RxDoctor Payments Data

Carrie Carda, MD

Obstetrics & Gynecology · Poplar Bluff, MONPI 1992777957

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,725 of the $22,319 with a category attached, or 70.5%. AbbVie accounts for 80.0% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2020 at $12,160 and has fallen 92.8% since, to $876 in 2025. Among obstetrics & gynecology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,319in general payments, 2019–2025

Across 335 payments — averaging $66.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Axonics, Inc.$1K
  • Novo Nordisk$314
  • Astellas Pharma US Inc$291
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$254
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
  • plus $2K from 39 others

What the payments were for

  • Speaking & faculty fees$15,72570%
  • Travel & lodging$9434%
  • Food & beverage$5,45424%
  • Education$1961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,319 in reported general payments places this provider in the 95th percentile of 750 obstetrics & gynecology providers in Missouri.

See all obstetrics & gynecology providers in Missouri

Medicare billing

Part B allowed, 2024
$5,597
Medicare patients
55
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$101,104
OzempicSemaglutide86$81,865
TrulicityDulaglutide73$76,497
LinzessLinaclotide52$29,515
JardianceEmpagliflozin42$28,147
FarxigaDapagliflozin Propanediol49$25,752
MyrbetriqMirabegron40$24,546
JanuviaSitagliptin Phosphate20$15,575
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,276
TrintellixVortioxetine Hydrobromide26$12,496
ProgesteroneProgesterone, Micronized445$9,808
Emgality PenGalcanezumab-Gnlm14$9,633
EliquisApixaban13$9,140
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,111
VascepaIcosapent Ethyl14$7,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$185$177,601158 claims
Novo NordiskOzempic$314$81,86586 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$26$40,09484 claims
AbbVieLinzess$17,848$29,51552 claims
Astellas Pharma US IncMyrbetriq$291$24,54640 claims
MerckJanuvia$66$15,57520 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$22$12,49626 claims
PfizerEliquis$119$9,14013 claims
Johnson & JohnsonXarelto$86$7,51213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 obstetrics & gynecology providers in Missouri.

Other obstetrics & gynecology in Poplar Bluff

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →